NTRK (Neurotrophic receptor tyrosine kinase)

P1/2, N=358, Recruiting, Xilio Development, Inc. | Trial completion date: Feb 2027 --> Sep 2028 | Trial primary completion date: Feb 2027 --> Sep 2028

For cases lacking these specific markers, VEGFR-targeted multikinase inhibitors (e.g., lenvatinib) remains the standard of care for RAIR-DTC...The therapeutic paradigm in thyroid cancer is shifting from non-selective multikinase inhibition toward molecularly matched, combination-based, and adaptively sequenced strategies. Early and comprehensive genomic profiling-including fusion detection-is essential to optimize treatment selection, address resistance, and expand precision therapy options across disease subtypes.

The false-positive rate was 13.3% in acinic cell carcinoma, histologically similar to secretory carcinoma. Luigi-Oral might be a useful alternative to IHC for screening NTRK fusion-positive rare SGC cases, and advances in digital pathology can facilitate implementation of an AI model in the NTRK screening workflow.

Most "Invalid" results were attributable to RNA degradation and resolved with freshly cut sections. These findings support the Idylla GeneFusion Assay as a rapid and practical frontline tool for NTRK fusion detection, particularly in settings with limited tissue or need for expedited decision-making, with reflex next-generation sequencing recommended for "Equivocal" cases or when fusion partner identification is required.

In conclusion, molecular profiling of BM allows selecting available treatment options for a substantial subset of patients. This study underscores the need for more systematic molecular testing in BM patients to guide systemic treatment decisions.

P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting

The patient was treated with temozolomide concurrently with radiotherapy, followed by tumor treating fields with adjuvant temozolomide...Various tyrosine kinase inhibitors, including entrectinib, larotrectinib, repotrectinib, and selitrectinib, along with bevacizumab, were considered to potentially prolong progression-free survival and overall survival and improve quality of life. We expect to highlight the rarity of this case while discussing the effectiveness of second-generation tyrosine kinase inhibitors in high-grade glioblastomas with rare gene fusions. We also hope to identify the appropriate timeline and treatment sequence for post-standard care, given the lack of official guidelines regarding cases this infrequent.

P2, N=45, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: May 2028 --> May 2027

Our findings expand the morphological and immunohistochemical spectrum of NTRK-rearranged uterine sarcomas, highlight important diagnostic pitfalls and raise the important question of driver versus passenger molecular events. Recognition of tumours with these unusual features is crucial, as NTRK-rearranged sarcomas frequently show aggressive clinical behaviour but are potentially amenable to targeted therapy with selective TRK inhibitors.

RET fusions and genetic alteration combination are independent prognostic markers for tumor recurrence of PTC, integrating tumors' genetic status into the 2025 ATA RSS system improves the accuracy of risk stratification for PTC.

P3, N=195, Recruiting, InnoPharmax Inc. | Not yet recruiting --> Recruiting

Recent developments in personalized medicine, including the introduction of new molecular diagnostic tools and targeted agents, have made considerable progress in the risk stratification and treatment strategies for papillary thyroid carcinoma. The current article reviews molecular mechanisms of activation of MAPK and PI3K/AKT pathways, their interaction, clinicopathological importance, and targeted treatments in papillary thyroid carcinoma.